A Feasibility Study to Test the Acceptability, Tolerance and Safety of Incremental Haemodialysis

Renal Failure Clinical Trial

— ENDURE  

Official title:

Effect of Incremental Introduction of Dialysis Versus Standard Care in Patients With End-stage Renal Disease: a Feasibility Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04268264
• Other study ID #: R2338
• Status: Completed
• Phase: N/A
• Start date: May 1, 2019
• Est. completion date: February 28, 2022

Study information

• Verified date: April 2022
• Source: Hull University Teaching Hospitals NHS Trust
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This feasibility study tests if patients find incremental HD acceptable, whether they tolerate the treatment as planned and to evaluate its safety. Over a period of 18-months, 20 participants will be recruited in to the study who are about to start HD therapy for ESRD. The participants will start HD incrementally (incremental HD group) reaching full dose HD over a period of approximately 15 weeks. The outcomes will be compared to a cohort of 40 matched patients who previously started HD in the conventional manner (historical controls, conventional HD group).

All patients will be followed-up for 6 months after first dialysis. Participants will be reviewed regularly during this time, and will undergo laboratory and bed-site monitoring tests. Acceptability and tolerance will be tested by documenting the numbers and percentages of patients who agree to participate and continue in the study. Patients who decline the invitation to join the study will be given the opportunity to express their reasons for declining to go on incremental HD (they will not play further part in the study). The safety of incremental HD will be tested by comparing the rates of pre-defined safety events in the incremental HD vs. conventional HD groups.

The impact of incremental HD on patients' residual renal function will be monitored using serial 24-hour urine collections, bio-impedance testing will be conducted to estimate changes in fluid load, measurements of quality-of-life will be undertaken by using patient KDQOL-SF v1.3 questionnaires. These tests will be repeated at regular intervals. Blood tests for estimation of residual renal function and markers of renal anemia, bone disease and cardiac load will be performed at regular intervals and will be compared between the two groups (incremental HD vs. conventional HD groups). These measurements will help in the evaluation of impact of incremental HD on patients' health and well-being. The completion rates of these tests will provide important information about whether they should be included in a future larger trial of incremental HD. Participants undergoing incremental HD will be invited to take part in semi-structured interviews aimed at exploring patients' experiences of receiving incremental HD and their participation in the study.

Data from this study will be used to test if it is feasible to use deaths (or a combination of deaths and cardiovascular events) as the main outcome measure in a future definitive trial on incremental HD. The data should enable a sample-size calculation for a future full-scale trial.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 54
• Est. completion date: February 28, 2022
• Est. primary completion date: February 28, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age > 18

• patients with CKD-5 who are about to start planned HD

• At least 3 months of prior specialist renal follow-up at the time of starting HD

• Able to meet all the study requirements

• Written signed informed consent.

Exclusion Criteria:

• Age < 18

• No prior contact with nephrologists for > 3 months

• Cross-over in to HD from peritoneal dialysis

• Currently undergoing HD therapy

• Any condition which in the opinion of the investigator makes the participant unsuitable for entry in to the study

• Participation in an interventional study in the preceding 6 weeks

• History of myocardial infarction in the preceding 3 months

• Inability to provide informed consent

• Inability to comply with the study schedule and follow-up.

Related Conditions & MeSH terms

• Hemodialysis Complication
• Morality
• Renal Failure
• Renal Insufficiency

Intervention

Procedure:
• Incremental haemodialysis
twice weekly haemodilysis at the start, gradually building up to full dose dialysis over a period of 15 weeks
• Conventional haemodialysis
three times weekly 4-hour long haemodialysis sessions from the start

Locations

Country	Name	City	State
United Kingdom	Hull University Teaching Hospitals NHS Trust	Hull	East Yorkshire

Sponsors (1)

Lead Sponsor	Collaborator
Hull University Teaching Hospitals NHS Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Acceptability: Recruitment rate	What proportion of eligible patients were recruited in to the trial?	6 months
Primary	Tolerance: Retention rate	What proportion of participants completed treatment as planned	6 months
Primary	Completion rates of non-routine tests	Completion rates of the non-routine tests a) the 24-hour urine collections, b) six-minute walk test, c) bio-impedance testing and d) quality of life questionnaires	6 months
Secondary	Mortality and cardiovascular event rates	Differences in mortality, and the composite of mortality and major cardiovascular events, between the interventional and control groups.	6 months
Secondary	Mechanistic 1: Rate of loss of residual renal function in the interventional group	Differences in renal urea clearance (in millilitres/min) from baseline	6 months
Secondary	Mechanistic 2:Changes in fluid load	Differences in overhydration volume (as measured through bio-impedance testing)	6 months
Secondary	Mechanistic 3:Quality of life	Changes in quality of life scores (using KDQOL-SF v 1.3) from baseline	6 months
Secondary	Mechanistic 4: Anaemia control	Changes in haemoglobin levels from baseline	6 months
Secondary	Mechanistic 5: Parathyroid hormone control	Changes in serum Parathyroid hormone, calcium and phosphate levels from baseline	6 months
Secondary	Mechanistic 6: Cardiac load	Changes in serum NT-proBNP measurements from baseline	6 months
Secondary	Safety 1: pre dialysis hyperkalaemia	Number of events: pre-dialysis hyperkalaemia (6.5 mmol/l or above)	6 months
Secondary	Safety 2: severe hypertension	Number of events: severe pre-dialysis hypertension (systolic BP > 180 and/or diastolic BP > 110 mmHg)	6 months
Secondary	Safety 3: Inter-dialytic weight gain	Number of events: interdialytic weight gain of greater than 4 kg	6 months